Ruth Ladenstein
Chaired the SIOPEN HR-NBL1 trial, the largest neuroblastoma trial ever, which set European standards for high-risk disease.
Overview
Ruth Ladenstein (Vienna) chaired SIOPEN HR-NBL1, the 3,000-patient trial that established busulfan-melphalan as the preferred myeloablative regimen for high-risk neuroblastoma and showed that adding interleukin-2 to dinutuximab beta immunotherapy adds toxicity without benefit. She has led SIOP Europe and coordinates the European neuroblastoma research network.
Pages like this
not linked directly; found by shared links- PairingCaution: IL-2 added to anti-GD2 therapy
Shares SIOPEN HR-NBL1, Neuroblastoma (paediatric).
- PersonJohn M. Maris
Shares Neuroblastoma (paediatric) and the tags paediatric, neuroblastoma.
- PersonNai-Kong V. Cheung
Shares Neuroblastoma (paediatric) and the tags paediatric, neuroblastoma.
- PersonYael P. Mossé
Shares Neuroblastoma (paediatric) and the tags paediatric, neuroblastoma.
- PersonMeredith Irwin
Shares Neuroblastoma (paediatric) and the tag neuroblastoma.
- PersonJeffrey S. Dome
Shares the tags paediatric, cooperative-group.
- PersonKara M. Kelly
Shares the tags paediatric, cooperative-group.
- PersonStefan S. Bielack
Shares the tags paediatric, cooperative-group.